Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity. Proc Natl Acad Sci U S A. 2023 Mar 28; 120(13):e2222073120.
View in:
PubMed
Characterization of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformational States on Infectious Virus Particles. J Virol. 2023 Feb 23; e0185722.
View in:
PubMed
Structural and Functional Characterization of Indane-Core CD4-Mimetic Compounds Substituted with Heterocyclic Amines. ACS Med Chem Lett. 2023 Jan 12; 14(1):51-58.
View in:
PubMed
Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound. J Virol. 2022 09 14; 96(17):e0063622.
View in:
PubMed
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Rep. 2022 06 14; 39(11):110924.
View in:
PubMed
Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation. J Virol. 2022 04 27; 96(8):e0166821.
View in:
PubMed
Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can Be Minimized by Distant State 1-Stabilizing Changes. J Virol. 2022 04 13; 96(7):e0187821.
View in:
PubMed
Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. Cell Rep. 2022 01 11; 38(2):110210.
View in:
PubMed
Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein. J Virol. 2022 02 09; 96(3):e0162621.
View in:
PubMed
Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. iScience. 2021 Nov 19; 24(11):103393.
View in:
PubMed
Identification of gp120 Residue His105 as a Novel Target for HIV-1 Neutralization by Small-Molecule CD4-Mimics. ACS Med Chem Lett. 2021 Nov 11; 12(11):1824-1831.
View in:
PubMed
Asymmetric Structures and Conformational Plasticity of the Uncleaved Full-Length Human Immunodeficiency Virus Envelope Glycoprotein Trimer. J Virol. 2021 11 23; 95(24):e0052921.
View in:
PubMed
Intra- and extra-cellular environments contribute to the fate of HIV-1 infection. Cell Rep. 2021 08 31; 36(9):109622.
View in:
PubMed
The opportunity cost of automated glycopeptide analysis: case study profiling the SARS-CoV-2 S glycoprotein. Anal Bioanal Chem. 2021 Dec; 413(29):7215-7227.
View in:
PubMed
Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern. bioRxiv. 2021 Aug 03.
View in:
PubMed
Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir. Cell Host Microbe. 2021 Jun 09; 29(6):904-916.e6.
View in:
PubMed
Analysis of glycosylation and disulfide bonding of wild-type SARS-CoV-2 spike glycoprotein. bioRxiv. 2021 Apr 01.
View in:
PubMed
Dual Pathways of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trafficking Modulate the Selective Exclusion of Uncleaved Oligomers from Virions. J Virol. 2021 01 13; 95(3).
View in:
PubMed
Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects. J Virol. 2021 03 01; 95(5).
View in:
PubMed
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg Microbes Infect. 2020 Dec; 9(1):2091-2093.
View in:
PubMed
Correction for Lu et al., "Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands". J Virol. 2020 Oct 27; 94(22).
View in:
PubMed
Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. J Virol. 2020 10 14; 94(21).
View in:
PubMed
Opening the HIV envelope: potential of CD4 mimics as multifunctional HIV entry inhibitors. Curr Opin HIV AIDS. 2020 09; 15(5):300-308.
View in:
PubMed
Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands. J Virol. 2020 08 17; 94(17).
View in:
PubMed
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020 08; 584(7821):450-456.
View in:
PubMed
Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike. bioRxiv. 2020 Jul 16.
View in:
PubMed
Slow Receptor Binding of the Noncytopathic HIV-2UC1 Envs Is Balanced by Long-Lived Activation State and Efficient Fusion Activity. Cell Rep. 2020 06 09; 31(10):107749.
View in:
PubMed
The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site. mBio. 2020 05 26; 11(3).
View in:
PubMed
The Conformational States of the HIV-1 Envelope Glycoproteins. Trends Microbiol. 2020 08; 28(8):655-667.
View in:
PubMed
Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein. PLoS Pathog. 2020 05; 16(5):e1008577.
View in:
PubMed
Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins. J Virol. 2020 05 04; 94(10).
View in:
PubMed
A New Family of Small-Molecule CD4-Mimetic Compounds Contacts Highly Conserved Aspartic Acid 368 of HIV-1 gp120 and Mediates Antibody-Dependent Cellular Cytotoxicity. J Virol. 2019 12 15; 93(24).
View in:
PubMed
CD4 Incorporation into HIV-1 Viral Particles Exposes Envelope Epitopes Recognized by CD4-Induced Antibodies. J Virol. 2019 11 15; 93(22).
View in:
PubMed
Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer. J Virol. 2019 11 01; 93(21).
View in:
PubMed
Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function. J Virol. 2019 06 15; 93(12).
View in:
PubMed
Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET. Nature. 2019 04; 568(7752):415-419.
View in:
PubMed
An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity. Cell Host Microbe. 2019 Apr 10; 25(4):578-587.e5.
View in:
PubMed
Robustness of signal detection in cryo-electron microscopy via a bi-objective-function approach. BMC Bioinformatics. 2019 Apr 03; 20(1):169.
View in:
PubMed
Blocking HIV-1 Infection by Chromosomal Integrative Expression of Human CD4 on the Surface of Lactobacillus acidophilus ATCC 4356. J Virol. 2019 04 15; 93(8).
View in:
PubMed
Conformational Differences between Functional Human Immunodeficiency Virus Envelope Glycoprotein Trimers and Stabilized Soluble Trimers. J Virol. 2019 02 01; 93(3).
View in:
PubMed
Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry. Nat Commun. 2019 01 03; 10(1):47.
View in:
PubMed
Visualization of HIV-1 RNA Transcription from Integrated HIV-1 DNA in Reactivated Latently Infected Cells. Viruses. 2018 09 30; 10(10).
View in:
PubMed
SOSIP Changes Affect Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Conformation and CD4 Engagement. J Virol. 2018 10 01; 92(19).
View in:
PubMed
A Small-Molecule CD4-Mimetic Compound Protects Bone Marrow-Liver-Thymus Humanized Mice From HIV-1 Infection. J Infect Dis. 2018 07 02; 218(3):471-475.
View in:
PubMed
Contribution of the gp120 V3 loop to envelope glycoprotein trimer stability in primate immunodeficiency viruses. Virology. 2018 08; 521:158-168.
View in:
PubMed
A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nat Commun. 2018 06 18; 9(1):2363.
View in:
PubMed
Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers. J Virol. 2018 06 15; 92(12).
View in:
PubMed
Folding DNA into a Lipid-Conjugated Nanobarrel for Controlled Reconstitution of Membrane Proteins. Angew Chem Int Ed Engl. 2018 02 19; 57(8):2072-2076.
View in:
PubMed
Publisher Correction: The ß20-ß21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions. Nat Commun. 2018 01 08; 9(1):158.
View in:
PubMed
Localization to detergent-resistant membranes and HIV-1 core entry inhibition correlate with HIV-1 restriction by SERINC5. Virology. 2018 02; 515:52-65.
View in:
PubMed
The ß20-ß21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions. Nat Commun. 2017 10 19; 8(1):1049.
View in:
PubMed
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nat Chem Biol. 2017 Oct; 13(10):1115-1122.
View in:
PubMed
Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States. J Virol. 2017 08 01; 91(15).
View in:
PubMed
An entry-competent intermediate state of the HIV-1 envelope glycoproteins. Receptors Clin Investig. 2017; 4(1).
View in:
PubMed
Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor. Virology. 2017 08; 508:90-107.
View in:
PubMed
BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. J Virol. 2017 06 01; 91(11).
View in:
PubMed
Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. J Virol. 2017 05 01; 91(9).
View in:
PubMed
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci Transl Med. 2017 03 15; 9(381).
View in:
PubMed
Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. J Virol. 2017 04 01; 91(7).
View in:
PubMed
Evaluation of the contribution of the transmembrane region to the ectodomain conformation of the human immunodeficiency virus (HIV-1) envelope glycoprotein. Virol J. 2017 02 16; 14(1):33.
View in:
PubMed
Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors. J Virol. 2017 03 01; 91(5).
View in:
PubMed
Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs. PLoS One. 2017; 12(2):e0170672.
View in:
PubMed
Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds. J Virol. 2017 Feb 01; 91(3).
View in:
PubMed
Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. AIDS Res Hum Retroviruses. 2017 05; 33(5):428-431.
View in:
PubMed
Characterization of two distinct early post-entry blocks to HIV-1 in common marmoset lymphocytes. Sci Rep. 2016 11 23; 6:37489.
View in:
PubMed
Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins. mBio. 2016 10 25; 7(5).
View in:
PubMed
Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. EBioMedicine. 2016 Oct; 12:208-218.
View in:
PubMed
Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine. 2016 Oct; 12:196-207.
View in:
PubMed
Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A. 2016 06 14; 113(24):E3413-22.
View in:
PubMed
Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. J Virol. 2016 05 15; 90(10):5031-5046.
View in:
PubMed
HIV-Host Interactions: Implications for Vaccine Design. Cell Host Microbe. 2016 Mar 09; 19(3):292-303.
View in:
PubMed
Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition. ACS Med Chem Lett. 2016 Mar 10; 7(3):330-4.
View in:
PubMed
Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4 + T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity. EBioMedicine. 2016 Jan; 3:122-134.
View in:
PubMed
Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. J Virol. 2016 02 15; 90(4):2021-30.
View in:
PubMed
HIV-1 Adapts To Replicate in Cells Expressing Common Marmoset APOBEC3G and BST2. J Virol. 2016 01 15; 90(2):725-40.
View in:
PubMed
Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host Microbe. 2015 Sep 09; 18(3):354-62.
View in:
PubMed
Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. J Virol. 2015 Aug; 89(16):8245-57.
View in:
PubMed
CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc Natl Acad Sci U S A. 2015 May 19; 112(20):E2687-94.
View in:
PubMed
Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer. PLoS One. 2015; 10(4):e0122111.
View in:
PubMed
Efficient human immunodeficiency virus (HIV-1) infection of cells lacking PDZD8. Virology. 2015 Jul; 481:73-8.
View in:
PubMed
Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology. 2015 Jan 15; 475:37-45.
View in:
PubMed
Structure of BMS-806, a Small-molecule HIV-1 Entry Inhibitor, Bound to BG505 SOSIP.664 HIV-1 Env Trimer. AIDS Res Hum Retroviruses. 2014 Oct; 30 Suppl 1:A151.
View in:
PubMed
A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nat Chem Biol. 2014 Oct; 10(10):845-52.
View in:
PubMed
Contribution of glutamine residues in the helix 4-5 loop to capsid-capsid interactions in simian immunodeficiency virus of macaques. J Virol. 2014 Sep; 88(18):10289-302.
View in:
PubMed
CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. J Virol. 2014 Jun; 88(12):6542-55.
View in:
PubMed
Contribution of PDZD8 to stabilization of the human immunodeficiency virus type 1 capsid. J Virol. 2014 May; 88(9):4612-23.
View in:
PubMed
Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission. J Virol. 2014 May; 88(9):5014-28.
View in:
PubMed
Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. Acc Chem Res. 2014 Apr 15; 47(4):1228-37.
View in:
PubMed
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol. 2014 Mar; 88(5):2633-44.
View in:
PubMed
Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency. Cell Host Microbe. 2013 Nov 13; 14(5):547-58.
View in:
PubMed
Reply to Subramaniam, van Heel, and Henderson: Validity of the cryo-electron microscopy structures of the HIV-1 envelope glycoprotein complex. Proc Natl Acad Sci U S A. 2013 Nov 05; 110(45):E4178-82.
View in:
PubMed
Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc Natl Acad Sci U S A. 2013 Nov 05; 110(45):18214-9.
View in:
PubMed
The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques. J Virol. 2014 Jan; 88(1):21-40.
View in:
PubMed
Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. J Am Chem Soc. 2013 Sep 04; 135(35):13113-20.
View in:
PubMed
A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization. PLoS One. 2013; 8(7):e69406.
View in:
PubMed
Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A. 2013 Jul 23; 110(30):12438-43.
View in:
PubMed
Virus-specific effects of TRIM5a(rh) RING domain functions on restriction of retroviruses. J Virol. 2013 Jul; 87(13):7234-45.
View in:
PubMed
Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization. ACS Med Chem Lett. 2013 Mar 14; 4(3):338-343.
View in:
PubMed
Characterization of a dual-tropic human immunodeficiency virus (HIV-1) strain derived from the prototypical X4 isolate HXBc2. Virology. 2013 Mar 30; 438(1):5-13.
View in:
PubMed
The HIV-1 gp120 major variable regions modulate cold inactivation. J Virol. 2013 Apr; 87(7):4103-11.
View in:
PubMed
Enhanced autointegration in hyperstable simian immunodeficiency virus capsid mutants blocked after reverse transcription. J Virol. 2013 Apr; 87(7):3628-39.
View in:
PubMed
The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. J Virol. 2013 Mar; 87(5):2549-62.
View in:
PubMed
Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques. Retrovirology. 2012 Dec 13; 9:106.
View in:
PubMed
Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibility. J Virol. 2013 Feb; 87(3):1884-9.
View in:
PubMed
HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism. Proteins. 2013 Feb; 81(2):271-90.
View in:
PubMed
A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry. Biochemistry. 2012 Sep 11; 51(36):7078-86.
View in:
PubMed
Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol. 2012 Sep; 19(9):893-9.
View in:
PubMed
Lineage-specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding. J Virol. 2012 Sep; 86(17):8974-86.
View in:
PubMed
Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid. J Virol. 2012 Aug; 86(16):8472-81.
View in:
PubMed
Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. J Med Chem. 2012 May 10; 55(9):4382-96.
View in:
PubMed
Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A. 2012 Apr 10; 109(15):5663-8.
View in:
PubMed
High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. J Virol. 2012 Feb; 86(4):2153-64.
View in:
PubMed
Role of CXCR4 internalization in the anti-HIV activity of stromal cell-derived factor-1a probed by a novel synthetically and modularly modified-chemokine analog. Exp Biol Med (Maywood). 2011 Dec; 236(12):1413-9.
View in:
PubMed
An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors. PLoS One. 2011; 6(11):e26731.
View in:
PubMed
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 2011 Sep; 7(9):e1002209.
View in:
PubMed
Liposomes for HIV prophylaxis. Biomaterials. 2011 Nov; 32(33):8663-8.
View in:
PubMed
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011 Oct; 85(19):9998-10009.
View in:
PubMed
Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques. PLoS One. 2011; 6(7):e21350.
View in:
PubMed
Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol. 2011 Sep; 85(17):8514-27.
View in:
PubMed
Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog. 2011 Jun; 7(6):e1002101.
View in:
PubMed
Determinants of the higher order association of the restriction factor TRIM5alpha and other tripartite motif (TRIM) proteins. J Biol Chem. 2011 Aug 12; 286(32):27959-70.
View in:
PubMed
Role of TRIM5a RING domain E3 ubiquitin ligase activity in capsid disassembly, reverse transcription blockade, and restriction of simian immunodeficiency virus. J Virol. 2011 Aug; 85(16):8116-32.
View in:
PubMed
Trafficking of some old world primate TRIM5a proteins through the nucleus. Retrovirology. 2011 May 15; 8:38.
View in:
PubMed
Graphene structures at an extreme degree of buckling. ACS Nano. 2011 Feb 22; 5(2):1395-400.
View in:
PubMed
Characterization of a core fragment of the rhesus monkey TRIM5a protein. BMC Biochem. 2011 Jan 04; 12:1.
View in:
PubMed
Hexagonal assembly of a restricting TRIM5alpha protein. Proc Natl Acad Sci U S A. 2011 Jan 11; 108(2):534-9.
View in:
PubMed
Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Bioorg Med Chem. 2011 Jan 01; 19(1):91-101.
View in:
PubMed
Adaptation of HIV-1 to cells expressing rhesus monkey TRIM5a. Virology. 2010 Dec 20; 408(2):204-12.
View in:
PubMed
Thermal stability of the human immunodeficiency virus type 1 (HIV-1) receptors, CD4 and CXCR4, reconstituted in proteoliposomes. PLoS One. 2010 Oct 13; 5(10):e13249.
View in:
PubMed
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14093-8.
View in:
PubMed
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010 Aug 13; 329(5993):811-7.
View in:
PubMed
Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. J Virol Methods. 2010 Sep; 168(1-2):155-61.
View in:
PubMed
Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe. 2010 Mar 18; 7(3):221-33.
View in:
PubMed
Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell. 2010 Mar 12; 37(5):656-67.
View in:
PubMed
Species-specific inhibition of foamy viruses from South American monkeys by New World Monkey TRIM5{alpha} proteins. J Virol. 2010 Apr; 84(8):4095-9.
View in:
PubMed
TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys. PLoS Pathog. 2010 Jan 22; 6(1):e1000738.
View in:
PubMed
A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. J Virol. 2010 Apr; 84(7):3147-61.
View in:
PubMed
Simian TRIM5alpha proteins reduce replication of herpes simplex virus. Virology. 2010 Mar 15; 398(2):243-50.
View in:
PubMed
Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A. 2010 Jan 19; 107(3):1166-71.
View in:
PubMed
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science. 2009 Nov 20; 326(5956):1123-7.
View in:
PubMed
Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology. 2010 Jan 20; 396(2):339-48.
View in:
PubMed
Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A. J Virol. 2009 Nov; 83(21):10951-62.
View in:
PubMed
A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction. J Virol. 2009 Oct; 83(20):10737-51.
View in:
PubMed
A rare null allele potentially encoding a dominant-negative TRIM5alpha protein in Baka pygmies. Virology. 2009 Aug 15; 391(1):140-7.
View in:
PubMed
Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain. J Virol. 2009 Sep; 83(17):8364-78.
View in:
PubMed
Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 2009 Apr; 5(4):e1000360.
View in:
PubMed
Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies. AIDS Res Hum Retroviruses. 2009 Mar; 25(3):319-28.
View in:
PubMed
Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation. J Virol. 2009 May; 83(9):4476-88.
View in:
PubMed
Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure. 2008 Nov 12; 16(11):1689-701.
View in:
PubMed
Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. J Virol. 2008 Dec; 82(23):11682-94.
View in:
PubMed
Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein. J Virol. 2008 Dec; 82(23):11669-81.
View in:
PubMed
The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J Virol. 2008 Dec; 82(23):11495-502.
View in:
PubMed
Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. J Virol. 2008 Nov; 82(22):11117-28.
View in:
PubMed
A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus. Virology. 2008 Sep 01; 378(2):233-42.
View in:
PubMed
Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem. 2008 May 08; 51(9):2638-47.
View in:
PubMed
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol. 2008 Feb; 6(2):143-55.
View in:
PubMed
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology. 2007 Dec 20; 369(2):400-10.
View in:
PubMed
Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors. J Virol. 2008 Jan; 82(1):346-57.
View in:
PubMed
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science. 2007 Sep 28; 317(5846):1930-4.
View in:
PubMed
HIV-1 envelope protein gp140 binding studies to human brain microvascular endothelial cells. Biochem Biophys Res Commun. 2007 Nov 23; 363(3):466-71.
View in:
PubMed
Crystal structure and structural mechanism of a novel anti-human immunodeficiency virus and D-amino acid-containing chemokine. J Virol. 2007 Oct; 81(20):11489-98.
View in:
PubMed
Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5alpha B-box 2 domain. J Virol. 2007 Oct; 81(19):10362-78.
View in:
PubMed
The ability of multimerized cyclophilin A to restrict retrovirus infection. Virology. 2007 Oct 10; 367(1):19-29.
View in:
PubMed
Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha. Virology. 2007 Sep 30; 366(2):234-44.
View in:
PubMed
Antibody binding in proximity to the receptor/glycoprotein complex leads to a basal level of virus neutralization. J Virol. 2007 Aug; 81(16):8809-13.
View in:
PubMed
Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol. 2007 Jun; 81(11):5579-93.
View in:
PubMed
Complex determinants within the Moloney murine leukemia virus capsid modulate susceptibility of the virus to Fv1 and Ref1-mediated restriction. Virology. 2007 Jul 05; 363(2):245-55.
View in:
PubMed
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 2007 Feb 15; 445(7129):732-7.
View in:
PubMed
Unique features of TRIM5alpha among closely related human TRIM family members. Virology. 2007 Apr 10; 360(2):419-33.
View in:
PubMed
The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J Virol. 2007 Mar; 81(5):2138-48.
View in:
PubMed
Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry. 2006 Sep 12; 45(36):10973-80.
View in:
PubMed
Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization. J Virol. 2006 Nov; 80(22):11404-8.
View in:
PubMed
Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry. J Virol. 2007 Jan; 81(2):532-8.
View in:
PubMed
Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology. 2006 Oct 10; 354(1):15-27.
View in:
PubMed
Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains. J Virol. 2006 Jul; 80(13):6198-206.
View in:
PubMed
Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker. J Virol. 2006 Jul; 80(14):6725-37.
View in:
PubMed
Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. J Virol. 2006 Jul; 80(14):6738-44.
View in:
PubMed
Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding. Virology. 2006 Sep 15; 353(1):234-46.
View in:
PubMed
Specific interaction of CXCR4 with CD4 and CD8alpha: functional analysis of the CD4/CXCR4 interaction in the context of HIV-1 envelope glycoprotein-mediated membrane fusion. Virology. 2006 Sep 15; 353(1):52-67.
View in:
PubMed
Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. J Virol. 2006 Jun; 80(11):5631-6.
View in:
PubMed
Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1. Virology. 2006 Aug 01; 351(2):404-19.
View in:
PubMed
Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. J Virol. 2006 May; 80(9):4388-95.
View in:
PubMed
Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci U S A. 2006 May 09; 103(19):7454-9.
View in:
PubMed
Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology. 2006 Jul 20; 351(1):112-20.
View in:
PubMed
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A. 2006 Apr 04; 103(14):5514-9.
View in:
PubMed
Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology. 2006 Jun 05; 349(2):300-15.
View in:
PubMed
SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development. Chem Biol. 2006 Jan; 13(1):69-79.
View in:
PubMed
Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an anti-HIV, D-amino acid-containing SMM-chemokine ligand. J Med Chem. 2005 Dec 15; 48(25):7923-4.
View in:
PubMed
Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors. J Virol. 2005 Dec; 79(24):15398-404.
View in:
PubMed
Structure of a V3-containing HIV-1 gp120 core. Science. 2005 Nov 11; 310(5750):1025-8.
View in:
PubMed
Retroviral restriction factor TRIM5alpha is a trimer. J Virol. 2005 Nov; 79(22):14446-50.
View in:
PubMed
Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol. 2005 Oct; 79(19):12132-47.
View in:
PubMed
Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains. J Virol. 2005 Oct; 79(20):12667-73.
View in:
PubMed
Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d. Virology. 2005 Sep 30; 340(2):277-84.
View in:
PubMed
TRIM5alpha association with cytoplasmic bodies is not required for antiretroviral activity. Virology. 2005 Dec 20; 343(2):201-11.
View in:
PubMed
Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J Virol. 2005 Aug; 79(15):9954-69.
View in:
PubMed
The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology. 2005 Jul 20; 338(1):154-72.
View in:
PubMed
An alternative conformation of the gp41 heptad repeat 1 region coiled coil exists in the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor. Virology. 2005 Jul 20; 338(1):133-43.
View in:
PubMed
The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. J Biol Chem. 2005 Jul 22; 280(29):26933-40.
View in:
PubMed
An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins. J Virol. 2005 May; 79(9):5616-24.
View in:
PubMed
Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. J Virol. 2005 May; 79(10):6068-77.
View in:
PubMed
The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates. J Virol. 2005 May; 79(10):6111-21.
View in:
PubMed
Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure. 2005 May; 13(5):755-68.
View in:
PubMed
Solubilization, stabilization, and purification of chemokine receptors using biosensor technology. Anal Biochem. 2005 Apr 15; 339(2):271-81.
View in:
PubMed
Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J Virol. 2005 Apr; 79(7):3930-7.
View in:
PubMed
Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol. 2005 Mar; 79(5):3139-45.
View in:
PubMed
Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol. 2005 Mar; 79(6):3500-8.
View in:
PubMed
Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers. Virology. 2005 Feb 05; 332(1):369-83.
View in:
PubMed
Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology. 2005 Jan 05; 331(1):33-46.
View in:
PubMed
Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology. 2004 Dec 05; 330(1):233-48.
View in:
PubMed
Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J Virol. 2004 Dec; 78(23):12975-86.
View in:
PubMed
Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol. 2004 Dec; 78(24):13901-10.
View in:
PubMed
Episomally replicating lentivirus vectors. 2004.
TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci U S A. 2004 Aug 10; 101(32):11827-32.
View in:
PubMed
Proteoliposomes containing an integral membrane protein having one or more transmembrane domains. 2004.
N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins. Virology. 2004 Jun 20; 324(1):140-50.
View in:
PubMed
Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J Virol. 2004 May; 78(10):5423-37.
View in:
PubMed
Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol. 2004 May; 78(9):4710-9.
View in:
PubMed
CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol. 2004 May; 78(10):5448-57.
View in:
PubMed
Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease. Virology. 2004 Apr 25; 322(1):168-81.
View in:
PubMed
Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. 2004.
Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol. 2004 Apr; 78(7):3742-52.
View in:
PubMed
Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A. 2004 Apr 06; 101(14):5036-41.
View in:
PubMed
HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004 Mar; 5(3):233-6.
View in:
PubMed
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004 Feb 26; 427(6977):848-53.
View in:
PubMed
Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry. 2004 Feb 24; 43(7):1928-38.
View in:
PubMed
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):2706-11.
View in:
PubMed
Envelope glycoprotein determinants of increased entry in a pathogenic simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys. AIDS Res Hum Retroviruses. 2004 Feb; 20(2):163-73.
View in:
PubMed
Simian virus 40-based replication of catalytically inactive human immunodeficiency virus type 1 integrase mutants in nonpermissive T cells and monocyte-derived macrophages. J Virol. 2004 Jan; 78(2):658-68.
View in:
PubMed
Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian Clade C HIV type 1 isolate. AIDS Res Hum Retroviruses. 2004 Jan; 20(1):27-40.
View in:
PubMed
Innate intracellular immunity to retroviruses. Harvey Lect. 2004-2005; 100:143-53.
View in:
PubMed
Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology. 2003 Oct 10; 315(1):124-34.
View in:
PubMed
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol. 2003 Oct; 77(19):10557-65.
View in:
PubMed
Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology. 2003 Sep 01; 313(2):387-400.
View in:
PubMed
Role of the gp120 inner domain beta-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits. Virology. 2003 Aug 15; 313(1):117-25.
View in:
PubMed
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell. 2003 Jul 25; 114(2):161-70.
View in:
PubMed
Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression. J Virol. 2003 Jun; 77(12):6645-59.
View in:
PubMed
Capture and reconstitution of G protein-coupled receptors on a biosensor surface. Anal Biochem. 2003 May 15; 316(2):243-50.
View in:
PubMed
Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. AIDS. 2003 Mar 28; 17(5):685-9.
View in:
PubMed
Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res Hum Retroviruses. 2003 Mar; 19(3):217-26.
View in:
PubMed
CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5. J Virol. 2003 Jan; 77(1):713-8.
View in:
PubMed
Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol. 2003 Jan; 77(1):726-31.
View in:
PubMed
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 2002 Dec 12; 420(6916):678-82.
View in:
PubMed
Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J Biol Chem. 2003 Jan 31; 278(5):3378-85.
View in:
PubMed
Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding. J Virol. 2002 Nov; 76(21):10791-800.
View in:
PubMed
Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res Hum Retroviruses. 2002 Nov 01; 18(16):1207-17.
View in:
PubMed
Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol. 2002 Oct; 76(19):9888-99.
View in:
PubMed
Blockade of HIV-1 infection of New World monkey cells occurs primarily at the stage of virus entry. J Exp Med. 2002 Aug 19; 196(4):431-45.
View in:
PubMed
Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region. J Biol Chem. 2002 Oct 25; 277(43):40397-402.
View in:
PubMed
Stimulation of enveloped virus infection by beta-amyloid fibrils. J Biol Chem. 2002 Sep 20; 277(38):35019-24.
View in:
PubMed
Beta-turn Phe in HIV-1 Env binding site of CD4 and CD4 mimetic miniprotein enhances Env binding affinity but is not required for activation of co-receptor/17b site. Biochemistry. 2002 Jun 04; 41(22):7038-46.
View in:
PubMed
Understanding the basis of CD4(+) T-cell depletion in macaques infected by a simian-human immunodeficiency virus. Vaccine. 2002 May 06; 20(15):1934-7.
View in:
PubMed
Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol. 2002 May; 76(9):4634-42.
View in:
PubMed
Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J Virol. 2002 Apr; 76(7):3511-21.
View in:
PubMed
Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines. J Biol Chem. 2002 May 17; 277(20):17476-85.
View in:
PubMed
Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines. J Exp Med. 2001 Dec 03; 194(11):1661-73.
View in:
PubMed
Human Mast cell progenitors can be infected by macrophagetropic human immunodeficiency virus type 1 and retain virus with maturation in vitro. J Virol. 2001 Nov; 75(22):10808-14.
View in:
PubMed
Ligand binding characteristics of CXCR4 incorporated into paramagnetic proteoliposomes. J Biol Chem. 2001 Oct 19; 276(42):38433-40.
View in:
PubMed
Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J Virol. 2001 Jun; 75(12):5646-55.
View in:
PubMed
Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys. J Virol. 2001 May; 75(9):4208-18.
View in:
PubMed
Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol. 2001 Apr; 75(7):3435-43.
View in:
PubMed
Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol. 2001 Mar; 75(5):2041-50.
View in:
PubMed
Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4. Biochemistry. 2001 Feb 13; 40(6):1662-70.
View in:
PubMed
Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol. 2001 Feb; 75(3):1165-71.
View in:
PubMed
Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure. 2000 Dec 15; 8(12):1329-39.
View in:
PubMed
Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo. J Virol. 2000 Dec; 74(24):11955-62.
View in:
PubMed
The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J Virol. 2000 Dec; 74(23):10984-93.
View in:
PubMed
Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. J Virol. 2000 Dec; 74(24):11972-6.
View in:
PubMed
Novel expression vectors and methods of use. 2000.
Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells. J Virol. 2000 Nov; 74(22):10690-8.
View in:
PubMed
A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem. 2000 Oct 27; 275(43):33516-21.
View in:
PubMed
Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A. 2000 Aug 01; 97(16):9026-31.
View in:
PubMed
Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol. 2000 Jun; 18(6):649-54.
View in:
PubMed
Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol. 2000 Jun; 74(12):5716-25.
View in:
PubMed
Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res Hum Retroviruses. 2000 May 20; 16(8):741-9.
View in:
PubMed
Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol. 2000 May; 74(9):4433-40.
View in:
PubMed
Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J Virol. 2000 May; 74(10):4746-54.
View in:
PubMed
Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain. J Virol. 2000 Apr; 74(8):3537-42.
View in:
PubMed
Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol. 2000 Feb; 74(4):1948-60.
View in:
PubMed
Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol. 2000 Feb; 74(4):1961-72.
View in:
PubMed
Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains. J Virol. 2000 Jan; 74(1):254-63.
View in:
PubMed
Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol. 1999 Dec; 73(12):10199-207.
View in:
PubMed
Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol. 1999 Dec; 73(12):10020-8.
View in:
PubMed
Vectors containing HIV packaging sequences, packaging-defective HIV vectors, and uses thereof. 1999.
HIV-1 entry inhibitors in the side pocket. Cell. 1999 Oct 29; 99(3):243-6.
View in:
PubMed
Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor. J Biol Chem. 1999 Oct 01; 274(40):28745-50.
View in:
PubMed
Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo. J Virol. 1999 Oct; 73(10):8873-9.
View in:
PubMed
Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol. 1999 Oct; 73(10):8120-6.
View in:
PubMed
Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Biochemistry. 1999 Jul 20; 38(29):9405-16.
View in:
PubMed
Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells. J Virol. 1999 Jul; 73(7):5373-80.
View in:
PubMed
Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 1999 Mar 05; 96(5):667-76.
View in:
PubMed
Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). J Biol Chem. 1999 Feb 12; 274(7):4115-23.
View in:
PubMed
Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2). J Virol. 1999 Feb; 73(2):976-84.
View in:
PubMed
Immunogenic peptides, antibodies, and uses thereof relating to CD4 receptor binding. 1999.
Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression. J Virol. 1999 Jan; 73(1):728-37.
View in:
PubMed
CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells. Cell Immunol. 1998 Nov 01; 189(2):160-8.
View in:
PubMed
Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol. 1998 Nov; 72(11):8952-60.
View in:
PubMed
Immunogenic peptides, antibodies, and uses thereof relating to CD4 receptor binding. 1998.
Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys. J Virol. 1998 Oct; 72(10):8437-45.
View in:
PubMed
The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques. J Exp Med. 1998 Sep 21; 188(6):1159-71.
View in:
PubMed
Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Virology. 1998 Sep 01; 248(2):394-405.
View in:
PubMed
Assay methods for Tat cell lines. 1998.
Stable TAT III cell lines, TAT III gene products, and assay methods (Art nucleotide segments, vector, cell lines, methods of preparation and use). 1998.
Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J Virol. 1998 Sep; 72(9):7620-5.
View in:
PubMed
Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol. 1998 Aug; 72(8):6332-8.
View in:
PubMed
The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. J Virol. 1998 Jul; 72(7):6113-8.
View in:
PubMed
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 1998 Jun 19; 280(5371):1884-8.
View in:
PubMed
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 1998 Jun 19; 280(5371):1949-53.
View in:
PubMed
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998 Jun 18; 393(6686):648-59.
View in:
PubMed
The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998 Jun 18; 393(6686):705-11.
View in:
PubMed
Structural interactions between chemokine receptors, gp120 Env and CD4. Semin Immunol. 1998 Jun; 10(3):249-57.
View in:
PubMed
CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol. 1998 Jun; 72(6):4694-703.
View in:
PubMed
The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry. Virology. 1998 May 10; 244(2):530-41.
View in:
PubMed
Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Gene Ther. 1998 May; 5(5):635-44.
View in:
PubMed
Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. J Virol. 1998 Apr; 72(4):3427-31.
View in:
PubMed
Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol. 1998 Apr; 72(4):3235-40.
View in:
PubMed
Reactive, neutralizing human anti-gp120 recombinant antibody, DNA coding the same and use therefore. 1998.
Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120. AIDS Res Hum Retroviruses. 1998 Feb 10; 14(3):191-8.
View in:
PubMed
A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol. 1998 Feb; 72(2):1160-4.
View in:
PubMed
Use of murine CXCR-4 as a second receptor by some T-cell-tropic human immunodeficiency viruses. J Virol. 1998 Feb; 72(2):1652-6.
View in:
PubMed
Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses. 1998 Jan 20; 14(2):151-5.
View in:
PubMed
A new classification for HIV-1. Nature. 1998 Jan 15; 391(6664):240.
View in:
PubMed
Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol. 1997 Dec; 71(12):9808-12.
View in:
PubMed
Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J Virol. 1997 Dec; 71(12):9722-31.
View in:
PubMed
CD4-independent binding of SIV gp120 to rhesus CCR5. Science. 1997 Nov 21; 278(5342):1470-3.
View in:
PubMed
Immunoglobulin V(H) usage during primary infection of rhesus monkeys with chimeric simian-human immunodeficiency viruses. J Virol. 1997 Nov; 71(11):8582-91.
View in:
PubMed
Inducible knockout of the interleukin-2 receptor alpha chain: expression of the high-affinity IL-2 receptor is not required for the in vitro growth of HTLV-I-transformed cell lines. Virology. 1997 Oct 27; 237(2):209-16.
View in:
PubMed
Vectors containing HIV packaging sequences, packaging-defective HIV vectors, and uses thereof. 1997.
Vectors expressing hybrid viruses methods of use and novel assays. 1997.
Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med. 1997 Aug 04; 186(3):405-11.
View in:
PubMed
Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol. 1997 Jun; 71(6):4847-51.
View in:
PubMed
Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J Virol. 1997 Jun; 71(6):4218-25.
View in:
PubMed
Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses. 1997 May 20; 13(8):647-56.
View in:
PubMed
CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997 May 05; 185(9):1681-91.
View in:
PubMed
High degree of sensitivity of the simian immunodeficiency virus (SIVmac) envelope glycoprotein subunit association to amino acid changes in the glycoprotein 41 ectodomain. AIDS Res Hum Retroviruses. 1997 Apr 10; 13(6):441-7.
View in:
PubMed
Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. J Mol Biol. 1997 Apr 04; 267(3):684-95.
View in:
PubMed
HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5. J Biol Chem. 1997 Mar 14; 272(11):6854-7.
View in:
PubMed
Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. J Virol. 1997 Mar; 71(3):2522-7.
View in:
PubMed
Cis-acting repression sequences, cis-acting anti-repression sequences, vectors, methods of preparation and use. 1997.
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature. 1997 Feb 13; 385(6617):645-9.
View in:
PubMed
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 1996 Nov 14; 384(6605):179-83.
View in:
PubMed
Perspective: research highlights at the Dana-Farber Cancer Institute Center for AIDS Research (CFAR). AIDS Res Hum Retroviruses. 1996 Nov 01; 12(16):1499-502.
View in:
PubMed
A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol. 1996 Oct; 70(10):6922-8.
View in:
PubMed
Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J Virol. 1996 Sep; 70(9):6136-42.
View in:
PubMed
The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996 Aug 29; 382(6594):829-33.
View in:
PubMed
Use of cis- and trans-acting viral regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes. Virology. 1996 Aug 15; 222(2):415-22.
View in:
PubMed
Effects of human immunodeficiency virus type 1 infection on programmed cell death in the presence or absence of Bcl-2. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 01; 12(4):321-8.
View in:
PubMed
Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses. 1996 Jul 01; 12(10):911-24.
View in:
PubMed
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996 Jun 28; 85(7):1135-48.
View in:
PubMed
Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 01; 12(2):99-106.
View in:
PubMed
Vaginal transmission of chimeric simian/human immunodeficiency viruses in rhesus macaques. J Virol. 1996 May; 70(5):3045-50.
View in:
PubMed
An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol. 1996 May; 70(5):3198-206.
View in:
PubMed
Cyclic AMP-mediated growth arrest is associated with increased expression of human T cell leukemia virus type I structural and transforming genes. AIDS Res Hum Retroviruses. 1996 Apr 10; 12(6):527-33.
View in:
PubMed
Targeting a foreign protein into virion particles by fusion with the Vpx protein of simian immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 01; 11(4):341-50.
View in:
PubMed
Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol. 1996 Mar; 70(3):1863-72.
View in:
PubMed
Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol. 1996 Mar; 70(3):1651-67.
View in:
PubMed
Molecular determinants of acute single-cell lysis by human immunodeficiency virus type 1. J Virol. 1996 Mar; 70(3):1340-54.
View in:
PubMed
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996 Feb; 70(2):1100-8.
View in:
PubMed
Conformation of the HIV-1 gp 120 envelope glycoprotein. Antibiot Chemother (1971). 1996; 48:184-7.
View in:
PubMed
Amino acid sequence requirements for the incorporation of the Vpx protein of simian immunodeficiency virus into virion particles. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15; 10(5):506-10.
View in:
PubMed
Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol. 1995 Nov; 69(11):7061-7.
View in:
PubMed
DNA end-joining in extracts from human cells. Biochem Biophys Res Commun. 1995 Oct 24; 215(3):987-93.
View in:
PubMed
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol. 1995 Sep; 69(9):5723-33.
View in:
PubMed
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol. 1995 Jul; 69(7):4413-22.
View in:
PubMed
T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus. J Exp Med. 1995 Jul 01; 182(1):21-31.
View in:
PubMed
Prior infection with a nonpathogenic chimeric simian-human immunodeficiency virus does not efficiently protect macaques against challenge with simian immunodeficiency virus. J Virol. 1995 Jul; 69(7):4569-71.
View in:
PubMed
Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains. J Virol. 1995 Jun; 69(6):3824-30.
View in:
PubMed
A defective HIV-1 vector for gene transfer to human lymphocytes. J Mol Med (Berl). 1995 Jun; 73(6):279-88.
View in:
PubMed
Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid). J Virol. 1995 May; 69(5):2801-10.
View in:
PubMed
Human immunodeficiency virus type 1 envelope glycoprotein-specific cytotoxic T lymphocytes in simian-human immunodeficiency virus-infected rhesus monkeys. Virology. 1995 Apr 20; 208(2):770-5.
View in:
PubMed
Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci U S A. 1995 Apr 11; 92(8):3137-41.
View in:
PubMed
Functional analysis of the vpx, vpr, and nef genes of simian immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 01; 8(4):335-44.
View in:
PubMed
Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. J Immunol. 1995 Jan 15; 154(2):893-906.
View in:
PubMed
Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol. 1995 Jan; 25(1):285-90.
View in:
PubMed
Determinants of human immunodeficiency virus type 1 entry in the CDR2 loop of the CD4 glycoprotein. J Virol. 1995 Jan; 69(1):166-71.
View in:
PubMed
Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol. 1995 Jan; 69(1):222-30.
View in:
PubMed
Effects of vif mutations on cell-free infectivity and replication of simian immunodeficiency virus. J Acquir Immune Defic Syndr (1988). 1994 Dec; 7(12):1228-36.
View in:
PubMed
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol. 1994 Dec; 68(12):8312-20.
View in:
PubMed
Functional association of cyclophilin A with HIV-1 virions. Nature. 1994 Nov 24; 372(6504):363-5.
View in:
PubMed
Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J Virol. 1994 Nov; 68(11):6836-47.
View in:
PubMed
Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120. Mol Immunol. 1994 Oct; 31(15):1149-60.
View in:
PubMed
Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J Virol. 1994 Sep; 68(9):5854-62.
View in:
PubMed
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol. 1994 Aug; 68(8):4821-8.
View in:
PubMed
Changes in the cytopathic effects of human immunodeficiency virus type 1 associated with a single amino acid alteration in the ectodomain of the gp41 transmembrane glycoprotein. J Virol. 1994 Jul; 68(7):4662-8.
View in:
PubMed
Art nucleotide segments, vectors, cell lines, methods of preparation and use. 1994.
Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J Virol. 1994 Jun; 68(6):3888-95.
View in:
PubMed
gp120-independent fusion mediated by the human immunodeficiency virus type 1 gp41 envelope glycoprotein: a reassessment. J Virol. 1994 Mar; 68(3):1977-82.
View in:
PubMed
Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J Virol. 1994 Feb; 68(2):674-80.
View in:
PubMed
Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J Virol. 1994 Jan; 68(1):469-84.
View in:
PubMed
Antigenic variation in gp120s from molecular clones of HIV-1 LAI. AIDS Res Hum Retroviruses. 1993 Dec; 9(12):1185-93.
View in:
PubMed
Towards a structure of the HIV-1 envelope glycoprotein gp120: an immunochemical approach. Philos Trans R Soc Lond B Biol Sci. 1993 Oct 29; 342(1299):83-8.
View in:
PubMed
Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol. 1993 Aug; 67(8):4557-65.
View in:
PubMed
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol. 1993 Jul; 67(7):3978-88.
View in:
PubMed
Monoclonal antibodies to HIV-1 gp120: a request. AIDS Res Hum Retroviruses. 1993 Jul; 9(7):695.
View in:
PubMed
Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies. AIDS. 1993 Jul; 7(7):919-23.
View in:
PubMed
Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol. 1993 Jun; 67(6):3674-9.
View in:
PubMed
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol. 1993 May; 67(5):2747-55.
View in:
PubMed
Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J Virol. 1992 Dec; 66(12):6997-7004.
View in:
PubMed
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol. 1992 Nov; 66(11):6489-95.
View in:
PubMed
Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody. J Clin Invest. 1992 Oct; 90(4):1467-78.
View in:
PubMed
Dissociation of unintegrated viral DNA accumulation from single-cell lysis induced by human immunodeficiency virus type 1. J Virol. 1992 Oct; 66(10):5777-87.
View in:
PubMed
The human T-cell leukemia virus (HTLV) transactivator (Tax) protein. Biochim Biophys Acta. 1992 Sep 14; 1114(1):19-29.
View in:
PubMed
Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol. 1992 Sep; 66(9):5635-41.
View in:
PubMed
Effects of CD4 synthetic peptides on HIV type I envelope glycoprotein function. J Immunol. 1992 Sep 01; 149(5):1809-16.
View in:
PubMed
Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology. 1992 Sep; 190(1):134-42.
View in:
PubMed
Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events. J Virol. 1992 Sep; 66(9):5516-24.
View in:
PubMed
Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol. 1992 Jul; 66(7):4570-5.
View in:
PubMed
Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins. J Virol. 1992 Jun; 66(6):3306-15.
View in:
PubMed
Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus. J Virol. 1992 Apr; 66(4):2389-97.
View in:
PubMed
Contribution of charged amino acids in the CDR2 region of CD4 to HIV-1 gp120 binding. J Acquir Immune Defic Syndr (1988). 1992; 5(2):204-10.
View in:
PubMed
Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr (1988). 1992; 5(7):639-46.
View in:
PubMed
Contribution of disulfide bonds in the carboxyl terminus of the human immunodeficiency virus type I gp120 glycoprotein to CD4 binding. J Acquir Immune Defic Syndr (1988). 1992; 5(1):78-81.
View in:
PubMed
Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J Acquir Immune Defic Syndr (1988). 1992; 5(6):591-9.
View in:
PubMed
Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol. 1991 Nov; 65(11):6188-93.
View in:
PubMed
Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity. J Virol. 1991 Sep; 65(9):5007-12.
View in:
PubMed
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A. 1991 Apr 15; 88(8):3195-9.
View in:
PubMed
Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol. 1991 Apr; 65(4):2119-23.
View in:
PubMed
Stable Tat III cell lines, Tat III gene products, and assay methods. 1991.
Role of the human immunodeficiency virus type I envelope glycoprotein in cytopathic effect. Adv Exp Med Biol. 1991; 300:193-9; discussion 200-1.
View in:
PubMed
Identification of membrane anchorage domains of the HIV-1 gp160 envelope glycoprotein precursor. J Acquir Immune Defic Syndr (1988). 1991; 4(1):34-40.
View in:
PubMed
The NF kappa B independent cis-acting sequences in HIV-1 LTR responsive to T-cell activation. J Acquir Immune Defic Syndr (1988). 1991; 4(2):173-7.
View in:
PubMed
Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector. J Virol. 1991 Jan; 65(1):532-6.
View in:
PubMed
Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein. J Virol. 1991 Jan; 65(1):281-91.
View in:
PubMed
A rapid method for quantitating the frequency of peripheral blood cells containing HIV-1 DNA. J Acquir Immune Defic Syndr (1988). 1991; 4(4):368-73.
View in:
PubMed
Changes in the transmembrane region of the human immunodeficiency virus type 1 gp41 envelope glycoprotein affect membrane fusion. J Virol. 1990 Dec; 64(12):6314-8.
View in:
PubMed
Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol. 1990 Dec; 64(12):5701-7.
View in:
PubMed
Identification of cis-acting repressive sequences within the negative regulatory element of human immunodeficiency virus type 1. J Virol. 1990 Oct; 64(10):5226-9.
View in:
PubMed
Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol. 1990 Jun; 64(6):3097-9.
View in:
PubMed
Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol. 1990 May; 64(5):2416-20.
View in:
PubMed
Protein kinase A-dependent binding of a nuclear factor to the 21-base-pair repeat of the human T-cell leukemia virus type I long terminal repeat. J Virol. 1990 Mar; 64(3):1264-70.
View in:
PubMed
A tripartite HIV-1 tat-env-rev fusion protein. EMBO J. 1990 Mar; 9(3):965-70.
View in:
PubMed
Mechanisms of infectivity and replication of HIV-1 and implications for therapy. Ann Emerg Med. 1990 Mar; 19(3):233-41.
View in:
PubMed
The T open reading frame of human immunodeficiency virus type 1. J Acquir Immune Defic Syndr (1988). 1990; 3(6):601-8.
View in:
PubMed
Effects on CD4 binding of anti-peptide sera to the fourth and fifth conserved domains of HIV-1 gp120. J Acquir Immune Defic Syndr (1988). 1990; 3(3):206-14.
View in:
PubMed
p21rex protein of HTLV-1. J Acquir Immune Defic Syndr (1988). 1990; 3(12):1135-9.
View in:
PubMed
Constitutive expression of HIV-1 tat protein in human Jurkat T cells using a BK virus vector. J Acquir Immune Defic Syndr (1988). 1990; 3(4):372-9.
View in:
PubMed
Identification of HIV-1 vpr product and function. J Acquir Immune Defic Syndr (1988). 1990; 3(1):11-8.
View in:
PubMed
Effects of long terminal repeat mutations on human immunodeficiency virus type 1 replication. J Virol. 1989 Sep; 63(9):4115-9.
View in:
PubMed
Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol. 1989 Sep; 63(9):4085-7.
View in:
PubMed
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1989 Aug; 86(15):5781-5.
View in:
PubMed
Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A. 1989 Jul; 86(13):5163-7.
View in:
PubMed
Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type I X-region genes transduced by a Herpesvirus saimiri vector. Proc Natl Acad Sci U S A. 1989 May; 86(9):3351-5.
View in:
PubMed
Antibodies to CD4 in individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1989 May; 86(9):3346-50.
View in:
PubMed
Synthesis of the 2-chloro analogues of 3'-deoxyadenosine, 2',3'-dideoxyadenosine, and 2',3'-didehydro-2',3'-dideoxyadenosine as potential antiviral agents. J Med Chem. 1989 May; 32(5):1135-40.
View in:
PubMed
Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetyltransferase enzyme. Proc Natl Acad Sci U S A. 1989 May; 86(10):3857-61.
View in:
PubMed
Response of the human T-cell leukemia virus type 1 long terminal repeat to cyclic AMP. J Virol. 1989 Apr; 63(4):1604-11.
View in:
PubMed
Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein. J Acquir Immune Defic Syndr (1988). 1989; 2(2):163-9.
View in:
PubMed
HTLV-I p27rex regulates gag and env protein expression. J Acquir Immune Defic Syndr (1988). 1989; 2(5):431-40.
View in:
PubMed
The potential for homeostatic regulation of the X region proteins of the human T cell leukemia virus type I. J Acquir Immune Defic Syndr (1988). 1989; 2(6):588-94.
View in:
PubMed
Identification of a protein encoded by the vpu gene of HIV-1. Nature. 1988 Aug 11; 334(6182):532-4.
View in:
PubMed
Subcellular localization of the human immunodeficiency virus trans-acting art gene product. J Virol. 1988 Jul; 62(7):2498-501.
View in:
PubMed
Trans-acting transcriptional factors. 1988.
Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc Natl Acad Sci U S A. 1988 Apr; 85(7):2071-5.
View in:
PubMed
The art gene product of human immunodeficiency virus is required for replication. J Virol. 1988 Feb; 62(2):655-8.
View in:
PubMed
A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature. 1988 Jan 07; 331(6151):78-81.
View in:
PubMed
Cis-acting sequences responsive to the rev gene product of the human immunodeficiency virus. J Acquir Immune Defic Syndr (1988). 1988; 1(5):441-52.
View in:
PubMed
Cell lines that express stably env gene products from three strains of HIV-1. J Acquir Immune Defic Syndr (1988). 1988; 1(4):317-23.
View in:
PubMed
Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc Natl Acad Sci U S A. 1987 Nov; 84(21):7408-12.
View in:
PubMed
Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci U S A. 1987 Nov; 84(22):8120-4.
View in:
PubMed
Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science. 1987 Sep 11; 237(4820):1351-5.
View in:
PubMed
Multiple sequence elements are required for regulation of human T-cell leukemia virus gene expression. Proc Natl Acad Sci U S A. 1987 Jul; 84(14):4919-23.
View in:
PubMed
HIV envelope-CD4 interaction not inhibited by synthetic octapeptides. Lancet. 1987 Jun 20; 1(8547):1428-9.
View in:
PubMed
Trans-activator gene of HTLV-II: interpretation. Science. 1987 Feb 27; 235(4792):1073.
View in:
PubMed
Expression of the art gene protein of human T-lymphotropic virus type III (HTLV-III/LAV) in bacteria. J Virol. 1987 Feb; 61(2):633-7.
View in:
PubMed
Mechanism of leukemogenesis by human T-cell leukemia virus types I and II: role of the lor gene. Cancer Detect Prev. 1987; 10(5-6):411-24.
View in:
PubMed
Transcription directed by the HIV long terminal repeat in vitro. AIDS Res Hum Retroviruses. 1987; 3(1):41-55.
View in:
PubMed
Replication and pathogenesis of the human T-cell leukemia/lymphotropic retroviruses. Haematol Blood Transfus. 1987; 31:395-403.
View in:
PubMed
Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature. 1987 Jan 1-7; 325(6099):67-70.
View in:
PubMed
Effects of mutations within the 3' orf open reading frame region of human T-cell lymphotropic virus type III (HTLV-III/LAV) on replication and cytopathogenicity. J Virol. 1986 Nov; 60(2):754-60.
View in:
PubMed
The 3' region of bovine leukemia virus genome encodes a trans-activator protein. EMBO J. 1986 Oct; 5(10):2585-9.
View in:
PubMed
Expression of reverse transcriptase activity of human T-lymphotropic virus type III (HTLV-III/LAV) in Escherichia coli. J Virol. 1986 Sep; 59(3):743-5.
View in:
PubMed
Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature. 1986 Jul 31-Aug 6; 322(6078):470-4.
View in:
PubMed
Identification of a protein encoded by the trans activator gene tatIII of human T-cell lymphotropic retrovirus type III. J Virol. 1986 Jul; 59(1):181-4.
View in:
PubMed
Trans-activator gene of HTLV-II induces IL-2 receptor and IL-2 cellular gene expression. Science. 1986 May 16; 232(4752):877-80.
View in:
PubMed
A second post-transcriptional trans-activator gene required for HTLV-III replication. Nature. 1986 May 22-28; 321(6068):412-7.
View in:
PubMed
The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell. 1986 Mar 28; 44(6):941-7.
View in:
PubMed
Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science. 1986 Mar 28; 231(4745):1549-53.
View in:
PubMed
Activation of enhancer sequences in type II human T-cell leukemia virus and bovine leukemia virus long terminal repeats by virus-associated trans-acting regulatory factors. J Virol. 1986 Mar; 57(3):738-44.
View in:
PubMed
Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III. Nature. 1986 Feb 13-19; 319(6054):555-9.
View in:
PubMed
Construction of recombinant murine retroviruses that express the human T-cell leukemia virus type II and human T-cell lymphotropic virus type III trans activator genes. J Virol. 1986 Jan; 57(1):379-84.
View in:
PubMed
Control of gene expression and the replication and pathogenesis of retroviruses. Important Adv Oncol. 1986; 159-72.
View in:
PubMed
Location of cis-acting regulatory sequences in the human T-cell leukemia virus type I long terminal repeat. Proc Natl Acad Sci U S A. 1985 Oct; 82(19):6502-6.
View in:
PubMed
The lor gene and pathogenesis of HTLV-I, -II, and -III. Cancer Res. 1985 Sep; 45(9 Suppl):4545s-4549s.
View in:
PubMed
trans-Activation of the human T-cell leukemia virus long terminal repeat correlates with expression of the x-lor protein. J Virol. 1985 Sep; 55(3):831-5.
View in:
PubMed
Expression of the x-lor gene of human T-cell leukemia virus I in Escherichia coli. J Virol. 1985 Aug; 55(2):497-9.
View in:
PubMed
Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III. Science. 1985 Jul 05; 229(4708):74-7.
View in:
PubMed
The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell. 1985 Jul; 41(3):813-23.
View in:
PubMed
A transcriptional activator protein encoded by the x-lor region of the human T-cell leukemia virus. Science. 1985 Jun 21; 228(4706):1430-4.
View in:
PubMed
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science. 1985 May 31; 228(4703):1091-4.
View in:
PubMed
Subcellular localization of the product of the long open reading frame of human T-cell leukemia virus type I. Science. 1985 Mar 08; 227(4691):1227-8.
View in:
PubMed
Trans activation of the bovine leukemia virus long terminal repeat in BLV-infected cells. Science. 1985 Jan 18; 227(4684):320-2.
View in:
PubMed
Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science. 1985 Jan 11; 227(4683):171-3.
View in:
PubMed
Structure and function of the genome of HTLV. Curr Top Microbiol Immunol. 1985; 115:177-209.
View in:
PubMed
Long terminal repeat structure of an American isolate of type I human T-cell leukemia virus. Virology. 1984 Dec; 139(2):340-5.
View in:
PubMed
Serological cross-reactivity between envelope gene products of type I and type II human T-cell leukemia virus. Proc Natl Acad Sci U S A. 1984 Dec; 81(23):7579-83.
View in:
PubMed
Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene. Science. 1984 Oct 05; 226(4670):57-61.
View in:
PubMed
Repetitive structure in the long-terminal-repeat element of a type II human T-cell leukemia virus. Proc Natl Acad Sci U S A. 1984 Aug; 81(15):4617-21.
View in:
PubMed
Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science. 1984 Jul 27; 225(4660):381-5.
View in:
PubMed
Structure of 3' terminal region of type II human T lymphotropic virus: evidence for new coding region. Science. 1984 Jul 27; 225(4660):419-21.
View in:
PubMed
Sequence of the envelope glycoprotein gene of type II human T lymphotropic virus. Science. 1984 Jul 27; 225(4660):421-4.
View in:
PubMed
Transforming potential of a human protooncogene (c-fps/fes) locus. Proc Natl Acad Sci U S A. 1984 May; 81(10):3039-43.
View in:
PubMed
Structure and function of human leukemia and AIDS viruses. Princess Takamatsu Symp. 1984; 15:187-96.
View in:
PubMed
Protein-coding capacities of polyadenylated RNAs from normal and neoplastic rat mammary tissues. Cancer Res. 1983 Apr; 43(4):1819-26.
View in:
PubMed
LTR regions of murine leukemia virus and human T cell leukemia virus as potential leukemogenic and pathogenic determinants. Human T cell Leukemia/Lymphoma Virus - Cold Spring Harbor Labs. 1983; 149-155.
Reflections and speculations regarding mechanisms of carcinogenesis. INSERM. 1983; 189-216.
Isolation and characterization of a human locus homologous to the transforming gene (v-fes) of feline sarcoma virus. J Biol Chem. 1982 Mar 25; 257(6):2730-3.
View in:
PubMed